University College London – Intensive Care Unit and Research Department of Clinical Physiology

UCL is one of the leading research universities worldwide with a wide range of expertise and facilities. The Intensive Care Unit and Research Department of Clinical Physiology has a major interest in sepsis and multi-organ dysfunction, in particular the role of mitochondrial dysfunction. The group focusses on basic, translational and clinical aspects including novel monitoring devices and diagnostics. One monitor (CardioQ oesophageal Doppler) is now commercially available in 30 countries, another (bladder tissue oxygen) is shortly to enter clinical trials, and a third (NADH fluorescence) is being developed in lab models. The Singer group has a highly sophisticated animal lab with sepsis models, with monitoring including haemodynamics, blood gas and biochemical analyses, metabolic cart, functional muscle testing (e.g. myography, treadmill), tissue oxygen and mitochondrial NADH redox state, and a wet lab offering ex vivo and in vitro mitochondrial biochemical and physiological assessments (e.g. Seahorse). Core platforms within UCL offer advanced technologies such as dual photon beam confocal microscopy, NGS, etc.

Involved researchers:

Mervyn Singer was appointed Professor of Intensive Care Medicine (at University College London in 2001. Singer sits on the Council of the International Sepsis Forum and is co-chair of the 2014 ESICM/SCCM Sepsis Redefinitions International Task Force. He is also a Senior Investigator of the UK National Institute of Health Research (2009-17) and Inflammation Theme Lead of the Infection/Immunity/Inflammation Board of the UCL/UCLH Biomedical Research Centre. He has been Clinical PI (or on the Steering Committee) of multiple academic and industry multicentre studies, many of which are related to sepsis (e.g. EU-funded CORTICUS study, UK DoH-funded PaCMan study).

Jo Spencer:  Following 20 years of training in the investigation of human cells and tissue in pathology departments, Prof. Spencer moved to the Department of Immunobiology at Guy’s Hospital in 2004.  She became Professor of Experimental Medicine in 2011. Prof. Spencer is involved in all areas of teaching at KCL including the delivery, organisation and administration of teaching to undergraduates and postgraduates. Prof. Spencer has been studying human B cells in health and disease for the last 30 years. In that time she has made key contributions to the definition of human B cell subsets and lineages. Her studies have impacted on human health, for example by contributing directly to the treatment of MALT lymphomas using H pylori eradication therapies. Current work is focused on the role of B cells and the microbiota in inflammatory and autoimmune diseases.